Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 2/20 | 0.48 |
| ▸ | CCND1 | P24385 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MC5R | P33032 | 5/20 | 0.47 |
| ▸ | MC3R | P41968 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MC4R | P32245 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2787635 | 0.90 | MAPT (0.47) | CDK4CCND1MAPTHPGDKMT2A | |
| SCHEMBL9943267 | 0.90 | MC5R (0.49) | CDK4CCND1MAPTMC5RMC3R | |
| SCHEMBL9943282 | 0.88 | MC5R (0.47) | CDK4CCND1MAPTMC5RMC3R | |
| SCHEMBL9943439 | 0.88 | MC5R (0.47) | CDK4CCND1MAPTMC5RMC3R | |
| SCHEMBL2786285 | 0.87 | KMT2A (0.47) | CDK4CCND1MAPTMC5RMC3R | |
| SCHEMBL2787985 | 0.83 | MC5R (0.43) | CDK4CCND1MAPTMC5RMC3R | |
| SCHEMBL2789272 | 0.83 | GOT1 (0.50) | CDK4CCND1MAPTMC5RMC3R | |
| SCHEMBL9943264 | 0.83 | GOT1 (0.50) | CDK4CCND1MAPTMC5RMC3R | |
| SCHEMBL9943315 | 0.83 | GOT1 (0.44) | CDK4CCND1MAPTMC5RMC3R | |
| SCHEMBL9943323 | 0.83 | GOT1 (0.44) | CDK4CCND1MAPTMC5RMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099815-B1 | NOVEL AMIDES ACTING ON THE ADENOSINE RECEPTORS | ANAMAR AB (SE) | 2012-06-20 | — | — | EP | claimed |
| EP-2099815-A2 | NOVEL AMIDES ACTING ON THE ADENOSINE RECEPTORS | Acure Pharma AB (SE) | 2009-09-16 | — | — | EP | claimed |
| WO-2008058679-A2 | NOVEL AMIDES ACTING ON THE ADENOSINE RECEPTORS | ACURE PHARMA AB (SE) | 2008-05-22 | — | — | WO | claimed |
| EP-2099815-B1 | NOVEL AMIDES ACTING ON THE ADENOSINE RECEPTORS | ANAMAR AB (SE) | 2012-06-20 | — | — | EP | disclosed |
| US-20100098629-A1 | Novel Amides Acting on the Adenosine Receptors | ACURE PHARMA AB (SE) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100098629-A1 | Novel Amides Acting on the Adenosine Receptors | ADORA1, ADORA3, ADORA2B | CDK4 3498/4885CCND1 2505/4885MAPT 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.